ERBB2 and breast carcinoma: In the NA‐PHER2 study of patients with ER‐positive, HER2‐positive early or locally advanced breast cancer, neoadjuvant palbociclib and fulvestrant plus trastuzumab and pertuzumab significantly reduced the expression of Ki‐67 and the tpCR rate was 27%.22